What is the efficacy of implantable cardioverter-defibrillator (ICD) therapy in asymptomatic patients?

Updated: Feb 13, 2017
  • Author: Daniel M Beyerbach, MD, PhD; Chief Editor: Jeffrey N Rottman, MD  more...
  • Print
Answer

Answer

A meta-analysis of 5 clinical trials that included 4317 patients with NYHA functional class I/II heart failure performed by Adabag et al suggested that asymptomatic patients with NYHA functional class I/II heart failure may benefit from cardiac resynchronization therapy. [22] This therapy has been shown to decrease all-cause mortality, reduce heart failure hospitalizations, and improve LVEF in these patients. The authors did caution that risks versus benefits do need to be taken into consideration for this group of patients.


Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!